Le Lézard
Classified in: Health
Subjects: LEG, POL, SCZ, AVO

AARP Ohio Statement on Strong Bipartisan Senate Finance Committee Vote for the Prescription Drug Pricing Reduction Act of 2019


COLUMBUS, Ohio, July 25, 2019 /PRNewswire/ -- AARP Ohio Advocacy & Communications Manager Luke Russell issued the following statement today, applauding Senator Rob Portman and Senator Sherrod Brown for voting in favor of the Senate Finance Committee's Prescription Drug Pricing Reduction Act of 2019:

(PRNewsfoto/AARP Ohio)

"AARP Ohio thanks both Senator Portman and Senator Brown for voting for the Prescription Drug Pricing Reduction Act today in committee. We commend the Senate Finance Committee for its strong bipartisan work to help seniors and all Americans, who pay the highest drug prices in the world.

"The time is now for legislation to rein in drug prices. Today's vote is a crucial first step leading up to full Senate action. AARP Ohio is deeply committed to winning this fight on behalf of our members and all Americans. We stand with senators who are committed to lowering drug prices and are working to advance this important bill.

"High drug prices disproportionately hurt older Americans, particularly Medicare Part D enrollees who take an average of 4.5 prescription medications each month. Most Medicare beneficiaries live on fixed incomes, with an average annual income of just over $26,000. The average annual price for a single specialty drug used on a chronic basis is now an astounding $79,000. Medications are simply not affordable when their prices exceed a person's annual income. Importantly the bill includes an out-of-pocket cap on prescription drugs for seniors in Medicare Part D and cracks down on drugmakers that raise prices higher than the rate of inflation. AARP also supported an amendment offered in committee to allow Medicare to negotiate for lower drug prices, but that amendment was not adopted. 

"On behalf of our 1.5 million members, AARP Ohio thanks Senator Brown, Senator Portman and the 17 other senators on the Senate Finance Committee who voted for the Prescription Drug Pricing Reduction Act of 2019."

About AARP
AARP is the nation's largest nonprofit, nonpartisan organization dedicated to empowering people 50 and older to choose how they live as they age. With a nationwide presence and nearly 38 million members, AARP strengthens communities and advocates for what matters most to families: health security, financial stability and personal fulfillment. AARP also produces the nation's largest circulation publications: AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org or follow @AARP and @AARPadvocates on social media.

 

SOURCE AARP Ohio


These press releases may also interest you

at 09:30
The "NeoDynamics AB - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering. Summary NeoDynamics AB (NeoDynamics) is a medical technology company that develops medical solutions for the early...

at 09:20
Europe Durable Medical Equipment (DME) Market by Type (Monitoring & Therapeutic Equipment [Blood Glucose Monitors, Infusion Pumps, Vital Sign Monitors, Oxygen Equipment], Medical Furniture [Medical Beds, Patient Lifts & Lift Chairs, Stretchers],...

at 09:17
ATL Technology, an interconnect development and manufacturing partner of top medical device firms, today announced the expansion of its Costa Rica operations and the divestiture of its Catheter Research Inc. ("CRI") business unit to Biomerics....

at 09:15
The "Cepheid - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering. Summary Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and...

at 09:15
Pharmatech Associates today announced the addition of Jahan Jowharchi as vice president, facilities and capital projects, to lead the expansion of the company's service offering in all areas of pharmaceutical facility design and engineering. Mr....

at 09:15
ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number 10457950). The technology claimed by the patent amplifies the effectiveness of gene editing in eukaryotic cells and can be...



News published on 25 july 2019 at 22:52 and distributed by: